Market Overview

RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea

Share:
Related REGN
Benzinga's Top Upgrades, Downgrades For February 13, 2017
The Market In 5 Minutes: Hello... Can You Hear Me?
What Makes Amgen A Compelling Buy In 2017? (Seeking Alpha)
Related AGN
After Merck Stops Study, What Remains Of The Alzheimer's Drug Pipeline?
6 Biggest Foreign Acquisitions Of American Companies In History
Top 10 Net Payout Yields For February 2017 (Seeking Alpha)

RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's (NYSE: AGN) DARPin may solidify the longer-term market position for Regeneron's (NASDAQ: REGN) Eylea.

The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."

RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.

RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.

Latest Ratings for REGN

DateFirmActionFromTo
Feb 2017PiperJaffrayUpgradesNeutralOverweight
Dec 2016BMO CapitalInitiates Coverage OnMarket Perform
Dec 2016BTIG ResearchUpgradesNeutralBuy

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (REGN + AGN)

View Comments and Join the Discussion!